January 2, 2018—BD (Becton, Dickinson and Company) recently announced it has completed the acquisition of CR Bard, Inc. The combined company, which will have approximately $16 billion in revenue, integrates Bard's 16,000 employees with BD's 65,000 employees.
A definitive agreement for the transaction was first announced in April 2017.
Bard Peripheral Vascular, a division of CR Bard, manufactures and markets devices for the treatment of peripheral and coronary artery diseases. Peripheral devices include the Lutonix 035 paclitaxel-coated balloon and the Atlas, Conquest, Dorado, and Ultraverse lines of percutaneous transluminal angioplasty balloons. For coronary interventions, Bard's portfolio includes the Bard Snare retrieval kit, the Porter hydrophilic guidewire for treatment of chronic total occlusions, and the True, True Flow, Vida BAV, and Vida PTV valvuloplasty balloon catheters.
With completion of the acquisition, Bard became a wholly owned subsidiary of BD.
advertisement
Featured Series
Tackling Complex Cases in Dialysis Access
Sponsored by Gore Medical
Related Articles
Ask the Experts: Which Forces Most Drive Platform Adoption in Superficial Venous Care?
A panel discusses how they navigate the technologies available for treating superficial venous disease and the factors that influence widespread adoption.
With Julianne Stoughton, MD, FACS; Thomas Proebstle, MD; Neil Khilnani, MD, FSIR, FACPh; and Steve Elias, MD, FACS, FACPh
Top 5 Articles From November 2017
Ten Steps
A standardized 10-step approach to the planning and sizing of a fenestrated endovascular aortic aneurysm repair.
By Jessica P. Simons, MD, MPH; and Andres Schanzer, MD
Thoracic Aortic Aneurysms: At What Size Should We Intervene?
Key factors to consider when selecting patients for TAA repair.
By Robert J. Hinchliffe, MD, FRCS; and Paul Hollering
Preoperative Risk Assessment for Optimal TEVAR Outcomes
Evaluating which imaging, risk stratification, and system-specific options to consider before thoracic endovascular aortic repair.
By Tristan R. A. Lane, PhD, BSc, MBBS, MRCS; Sadie Syed, MD, MBBS, FRCA; Richard Gibbs, MD, MBChB, FRCS; and Colin D. Bicknell, MD, FRCS
Classification of Aortic Pathologies
A brief review of thoracic aortic aneurysms and acute aortic syndrome, including classic aortic dissection, intramural hematoma, and penetrating aortic ulcer.
By Sharif H. Ellozy, MD
TEVAR and Reintervention: How to Manage Endoleaks and False Lumen Perfusion
Treatment approaches for thoracic aortic aneurysm and thoracic aortic dissection failures.
By Zachary Kostun, MD; and Manish Mehta, MD, MPH
Top 5 from CIToday's Current Issue
Trends in United States TAVR Practice
An update on where TAVR is going as the technology matures in the United States.
By John C. Messenger, MD
Worldwide Trends in TAVR
By Ted E. Feldman, MD, MSCAI, FACC, FESC; and Bernard Prendergast, BMedSci, BM BS, MRCP, DM, FRCP, FESC
Current Status and Expectations for Low-Risk TAVI Trials
An expert opinion on how current clinical trials will impact the future of TAVI procedures in low-risk patients.
With Marc Dweck, MD, PhD
Risk Assessment for Transcatheter Aortic Valve Replacement
Understanding STS score, EuroSCORE, and frailty indices.
By Troels Højsgaard Jørgensen, MD; and Lars Søndergaard, MD, DMSc
Trends in European TAVI Practice
Current application of TAVI in Europe.
